Genentech, Inc.

Yves Dubaquie

Henry Bernard Lowman

Paul J Fielder

Deborah L Mortensen

Ellen Filvaroff

Ross Graham Clark

Iain C A F Robinson

Andrea Cochran

Yvonne Man-Yee Chen

Nicholas Skelton

The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.

Method for treating cartilage disorders

IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16, 25, 49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.

IGF-I protein variants for treating IGFBP-1-related disorders

Article of manufacture

Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant

IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively.

IGF-I point variants

IGF-I variants

IGF-I variants having an alanine, glycine, or serine amino acid residue at position 16,25,49 or at positions 3 and 49 of native-sequence IGF-I are provided that are useful to treat a disorder characterized by dysregulation of the GH/IGF axis in a mammal, such as a renal disorder.

Insulin-like growth factor-1 protein variants

Growing community of inventors

Lawrenceville, NJ, United States of America

Yves Dubaquie